scholarly journals Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Metastasis from Breast Cancer: A Preliminary Report on 4 Cases

2020 ◽  
Author(s):  
Jun-Hui Yu ◽  
Yu Feng ◽  
Xin-Bao Li ◽  
Cheng-Yan Zhang ◽  
Feng Shi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Intraperitoneal Chemotherapy ◽  
Cytoreductive Surgery ◽  
Hyperthermic Intraperitoneal Chemotherapy ◽  
Perioperative Period ◽  
Median Number ◽  
International Consensus ◽  
Serious Adverse Events ◽  
Integrated Therapy ◽  
Treat Breast Cancer

Abstract Background: Breast cancer (BC) has the highest morbidity and the fifth mortality rate among women in China. Peritoneal metastases from BC is a rare disease and no guideline or international consensus for it. Objective: To summarise our experiences in cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) to treat breast cancer peritoneal carcinomatosis (BC PC).Methods: 4 BC PC patients underwent CRS+HIPEC were enrolled in this study. The clinic-pathologic characteristics and overall survival (OS) were collected and analysed.Result: The average age at CRS+HIPEC was 59.8 years. The average time of CRS+HIPEC was 8.8 h. The median number of resected organ areas was 7. OS from CRS+HIPEC were 31, 28, 16 and 52 months. There were no serious adverse events (SAEs) during the perioperative period.Conclusions: The 4 cases provided evidence that integrated therapy with CRS+HIPEC may be a promising strategy to improve the outcome for BC PC patients.

scholarly journals Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Metastasis from Breast Cancer: A Preliminary Report on 4 Cases

2020 ◽  
Author(s):  
Jun-Hui Yu ◽  
Yu Feng ◽  
Xin-Bao Li ◽  
Cheng-Yan Zhang ◽  
Feng Shi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Intraperitoneal Chemotherapy ◽  
Cytoreductive Surgery ◽  
Hyperthermic Intraperitoneal Chemotherapy ◽  
Perioperative Period ◽  
Median Number ◽  
International Consensus ◽  
Serious Adverse Events ◽  
Integrated Therapy ◽  
Treat Breast Cancer

Abstract Background: Breast cancer (BC) has been ranked as the first malignancy most common and the fifth in mortality rate among women in China [1]. Peritoneal metastases from BC is a rare disease and no guideline or international consensus for it. Objective: To summarize our experiences in cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) to treat breast cancer peritoneal carcinomatosis (BC PC). Methods: This is a retrospective study on the 4 BC PC patients underwent CRS+HIPEC at our center. The clinicopathological features and treatment details on the BC PC patients were analyzed. Result: The average age at CRS+HIPEC was 59.8 years. The average duration of CRS+HIPEC was 8.8 h. The median number of resected organ areas was 7. Overall survival from CRS+HIPEC were 31, 28, 16 and 52 months. There were no serious adverse events (SAEs) during perioperative period. Conclusions: The 4 cases provided evidence that integrated therapy with CRS+HIPEC may be a promising strategy to improve outcome for BC PC patients.

scholarly journals Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Metastasis from Breast Cancer: A Preliminary Report on 4 Cases

2020 ◽  
Author(s):  
Jun-Hui Yu ◽  
Yu Feng ◽  
Xin-Bao Li ◽  
Cheng-Yan Zhang ◽  
Feng Shi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Overall Survival ◽  
Intraperitoneal Chemotherapy ◽  
Cytoreductive Surgery ◽  
Hyperthermic Intraperitoneal Chemotherapy ◽  
Perioperative Period ◽  
Median Number ◽  
International Consensus ◽  
Serious Adverse Events ◽  
Integrated Therapy

Abstract Background: Breast cancer (BC) has been ranked as the first malignancy most common and the fifth in mortality rate among women in China. Peritoneal metastases from BC is a rare disease and no guideline or international consensus for it. Objective: To summarise our experiences in cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) to treat breast cancer peritoneal carcinomatosis (BC PC). Methods: 4 BC PC patients underwent CRS+HIPEC were enrolled in this study. The clinic-pathologic characteristics and overall survival (OS) were collected and analysed. Result: The average age at CRS+HIPEC was 59.8 years. The average time of CRS+HIPEC was 8.8 h. The median number of resected organ areas was 7. Overall survival from CRS+HIPEC were 31, 28, 16 and 52 months. There were no serious adverse events (SAEs) during the perioperative period. Conclusions: The 4 cases provided evidence that integrated therapy with CRS+HIPEC may be a promising strategy to improve the outcome for BC PC patients.

scholarly journals Early Data Of Patients With Pseudomyxoma Peritonei From Appendiceal Origin Treated By A Strategy Of Cytoreductive Surgery And Hyperthermic Intraperitoneal Chemotherapy

2016 ◽  
Vol 26 (5) ◽  
pp. 88-92
Author(s):  
Algirdas Šlepavičius ◽  
Vaidotas Turskis ◽  
Vitalija Nutautienė ◽  
Vitalijus Eismontas
Keyword(s):  
Intraperitoneal Chemotherapy ◽  
Cytoreductive Surgery ◽  
Hyperthermic Intraperitoneal Chemotherapy ◽  
Peritoneal Cancer Index ◽  
Median Number ◽  
University Hospital ◽  
Curative Intent ◽  
Peritoneal Cancer ◽  
The Moment

Background. Appendiceal peritoneal pseudomyxoma (PMP) is very rare disease and its longterm prognosis is poor. The aim of this study was to evaluate the results of an aggressive treatment approach used in our institution for the last 4 years. Methods. We selected all patients with PMP from appendiceal origin who were treated by cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) at the Klaipeda University Hospital between January 2012 and January 2016. Data from all patients with PMP arising from the appendix were retrospectively collected and analyzed. Treatment consisted of complete surgical cytoreduction , followed by hyperthermic intraperitoneal chemotherapy with mitomycin at 42°C over 90 minutes. Ronnett’s hystologic classification was used for tumor grading. Results. A total of 6 patients underwent cytoreduction and peritonectomy plus HIPEC. Median age at diagnosis was 57 years (range, 39-67). All our patients were female. The previous surgery score at the moment of admission was PSS-2 for three patients, PSS-3 for 3 patients. Four patients were diagnosed as diffuse peritoneal adenomucinosis (DRAM) and two as peritoneal mucinous carcinomatosis( PMCA). In all of the patients, optimal cytoreduction CC-0 (5 patients) and CC-1 (one patient) was achieved. The median peritoneal cancer index (PCI) was 17 (range, 14-25) as an indicator of disease extension.The median number of visceral resections performed per patient was 3 (range, 1-5). The median duration of CRS/HIPEC was 8 hours and 10 minutes (range, 7 hours and10 min. to 9 hours 20 min). Mean postoperative stay was 13 days (range, 8-18). The 30 days postoperative and in-hospital mortality were zero . One patient experienced temporary haemorhagic cystitis. The mean follow-up period was 28 months ( range, 8-45). At the time of analysis all patients are alive and without recurrence. Conclusions PMP from appendiceal origin can be treated with curative intent in a large percentage of cases by cytoreductive surgery associated with HIPEC. This new approach could be performed safely with acceptable morbidity and mortality in selected patients treated in specialized centers.

scholarly journals Physiologic and hemodynamic changes in patients undergoing open abdominal cytoreductive surgery with hyperthermic intraperitoneal chemotherapy

2021 ◽  
Vol 49 (1) ◽  
pp. 030006052098326
Author(s):  
Myoung Hwa Kim ◽  
Young Chul Yoo ◽  
Sun Joon Bai ◽  
Kang-Young Lee ◽  
Nayeon Kim ◽  
...  
Keyword(s):  
Body Temperature ◽  
Systemic Vascular Resistance ◽  
Vascular Resistance ◽  
Intraperitoneal Chemotherapy ◽  
Cytoreductive Surgery ◽  
Hyperthermic Intraperitoneal Chemotherapy ◽  
Resistance Index ◽  
Volume Index ◽  
Hemodynamic Changes ◽  
Arterial Blood

Objective We aimed to determine the physiological and hemodynamic changes in patients who were undergoing hyperthermic intraperitoneal chemotherapy (HIPEC) cytoreductive surgeries. Methods This prospective, observational study enrolled 21 patients who were undergoing elective cytoreductive surgery with HIPEC at our hospital over 2 years. We collected vital signs, hemodynamic parameters including global end-diastolic volume index (GEVI) and extravascular lung water index (ELWI) using the VolumeView™ system, and arterial blood gas analysis from all patients. Data were recorded before skin incision (T1); 30 minutes before HIPEC initiation (T2); 30 (T3), 60 (T4), and 90 (T5) minutes after HIPEC initiation; 30 minutes after HIPEC completion (T6); and 10 minutes before surgery completion (T7). Results Patients showed an increase in body temperature and cardiac index and a decrease in the systemic vascular resistance index. GEDI was 715.4 (T1) to 809.7 (T6), and ELWI was 6.9 (T1) to 7.3 (T5). Conclusions HIPEC increased patients’ body temperature and cardiac output and decreased systemic vascular resistance. Although parameters that were extracted from the VolumeView™ system were within their normal ranges, transpulmonary thermodilution approach is helpful in intraoperative hemodynamic management during open abdominal cytoreductive surgery with HIPEC. Trial registry name: ClinicalTrials.gov Trial registration number: NCT02325648 URL: https://clinicaltrials.gov/ct2/results?cond=NCT02325648&term

Sclerosing Encapsulating Peritonitis after Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Description of 4 Cases

2021 ◽  
Vol 47 (2) ◽  
pp. e14-e15 ◽  
Author(s):  
Fernando Arias-Amézquita ◽  
Eduardo Londoño-Schimmer ◽  
Jorge Miguel Otero-Bernal ◽  
Camilo Cétares ◽  
Martha Mora ◽  
...  
Keyword(s):  
Intraperitoneal Chemotherapy ◽  
Cytoreductive Surgery ◽  
Hyperthermic Intraperitoneal Chemotherapy ◽  
Sclerosing Encapsulating Peritonitis ◽  
Encapsulating Peritonitis

scholarly journals Cytoreductive Surgery Combined with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Metastasis from Colorectal Cancer

2020 ◽  
Vol 33 (06) ◽  
pp. 372-376
Author(s):  
Hideaki Yano
Keyword(s):  
Colorectal Cancer ◽  
Intraperitoneal Chemotherapy ◽  
Cytoreductive Surgery ◽  
Peritoneal Metastasis ◽  
Hyperthermic Intraperitoneal Chemotherapy ◽  
Peritoneal Cancer Index ◽  
Systemic Disease ◽  
Good Reason ◽  
Standard Of Care ◽  
Peritoneal Cancer

AbstractPeritoneal metastasis from colorectal cancer (PM-CRC) is used to be considered a systemic and fatal condition; however, it has been growingly accepted that PM-CRC can still be local disease rather than systemic disease as analogous to liver or lung metastasis.Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) is now considered an optimal treatment for PM-CRC with accumulating evidence. There is a good reason that CRS + HIPEC, widely accepted as a standard of care for pseudomyxoma peritonei (PMP), could be a viable option for PM-CRC given a similarity between PM-CRC and PMP.Recent years have also seen that modern systemic chemotherapy with or without molecular targeted agents can be effective for PM-CRC. It is possible that neoadjuvant or adjuvant chemotherapy combined with CRS + HIPEC could further improve outcomes.Patient selection, utilizing modern images and increasingly laparoscopy, is crucial. Particularly, diagnostic laparoscopy is likely to play a significant role in predicting the likelihood of achieving complete cytoreduction and assessing the peritoneal cancer index score.

Sign in / Sign up

Export Citation Format

Share Document